StockNow
Log in
Global Markets

GSK (GSK LN) Q2 2026 (GBP): adj. EPS 0.505 (exp. 0.468), Revenue 8.41bln (exp. 8.13bln). FY outlook confirmed, with additional details.

StockNow breaking-news AI analysis

GSK beat Q2 expectations and narrowed revenue/profit guidance to the upper half, while focusing on R&D acceleration following the $10.6bn Nuvalent deal and Jideytro's FDA approval.

News detail

Intends to accelerate its R&D and late-stage pipeline portfolio.Sales Breakdown: Medicines: 3.8bln, +14% Vaccines: 2.3bln, +8% General Medicine: 2.3bln, -9% FY26 Guidance Turnover: 3-5%, upper-half of the band (prev. guided 3-5%) Core Operating Profit: 7-9%, upper-half of the band (prev. guided 7-9%) Core EPS: 7-9%, lower-half of the band (prev. guided 7-9%)

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

Geopolitics

The draft agreed to by Iranian and Omani negotiators awaits final approval from Iran’s supreme leader, two regional officials told The Associated Press on Wednesday

Geopolitics

Only 'one or two issues' remain unresolved in Iran-Oman talks, a senior diplomatic source tells Al Jazeera